KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Leases (2019 - 2025)

Historic Operating Leases for Xenon Pharmaceuticals (XENE) over the last 7 years, with Q3 2025 value amounting to $6.8 million.

  • Xenon Pharmaceuticals' Operating Leases fell 1865.7% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 1865.7%. This contributed to the annual value of $7.6 million for FY2024, which is 2038.73% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Operating Leases is $6.8 million, which was down 1865.7% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Operating Leases registered a high of $10.4 million during Q1 2023, and its lowest value of $2.6 million during Q3 2021.
  • In the last 5 years, Xenon Pharmaceuticals' Operating Leases had a median value of $7.9 million in 2022 and averaged $7.6 million.
  • In the last 5 years, Xenon Pharmaceuticals' Operating Leases skyrocketed by 126063.83% in 2021 and then crashed by 2038.73% in 2024.
  • Xenon Pharmaceuticals' Operating Leases (Quarter) stood at $7.7 million in 2021, then rose by 29.99% to $9.9 million in 2022, then fell by 3.45% to $9.6 million in 2023, then dropped by 20.39% to $7.6 million in 2024, then fell by 10.65% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $7.3 million for Q2 2025, and $7.3 million during Q1 2025.